The drug “Molnupiravir” for the treatment of Covid-19 was introduced in India under the brand name “Molnaflu”.

Hyderabad, January 06 (Agency). Aurobindo Pharma Limited has introduced the drug “Molnupiravir” for the treatment of COVID-19 under the name “Molnaflu” in India. A press release issued by the Hyderabad-based drug manufacturer states that Molnupiravir is intended for the treatment of adult Covid-19 patients admitted to hospital.

Earlier, Molnupiravir received an “Emergency Use Approval” from the Central Drugs Standard Control Organization (CDSCO). Last year, Aurobindo Pharma partnered with Merck Sharp Dohme, Singapore, a US-based subsidiary of Merck & Co, for supply and production in low- and middle-income countries.

Read also: Ratnakar Kumar’s Bhojpuri’s “Babul” premieres.

Aurobindo K. Vice President and CEO Nithyananda Reddy said: “We are delighted to have received timely approval from DGCI for the licensed use of Molnupiravir. “This will allow affordable treatment for patients with COVID-19 and will enable us to fight the pandemic through effective and high quality medicines.”

Read More :   Deadly driver, two trucks collided

The post-treatment drug Covid-19 “Molnupiravir” introduced in India under the name “Molnaflu” first appeared on Khulasaa.in.

Related Posts